Table 2.
Histopathologic assessment of various antiarthritic agents in the Tg197 murine model of rheumatoid arthritis
% of total at indicated HS scores | |||||||
Treatment | Joints scored | HS 0 | HS 1 | HS 2 | HS 3 | HS 4 | Mean HS ± standard error |
Untreated | 20 | 0 | 0 | 20 | 30 | 50 | 3.30 ± 0.18 |
WFI | 20 | 0 | 0 | 15 | 50 | 35 | 3.20 ± 0.15 |
Diacerein 2 mg/kg daily | 18 | 5 | 23 | 50 | 11 | 11 | 2.00 ± 0.24* |
Diacerein 20 mg/kg daily | 16 | 6 | 19 | 25 | 44 | 6 | 2.25 ± 0.26* |
Diacerein 60 mg/kg daily | 20 | 5 | 15 | 35 | 20 | 25 | 2.45 ± 0.26* |
Methotrexate 1 mg/kg three times weekly | 12 | 0 | 0 | 8 | 25 | 67 | 3.58 ± 0.19 |
Dexamethasone 0.5 mg/kg daily | 12 | 25 | 67 | 8 | 0 | 0 | 0.83 ± 0.16* |
CB0006 5 mg/kg weekly | 12 | 100 | 0 | 0 | 0 | 0 | 0* |
Histopathogic score (HS) was evaluated on ankle joints of untreated or treated Tg197 mice at age 7 weeks. In the case of the methotrexate, dexamethasone, and anti-tumor necrosis factor antibody treatments, the data shown are derived from one representative from three independent experiments. *P < 0.05 versus untreated or water for injection (WFI) treated Tg197 control groups.